Product news!

LDH test for COVID-19 patients

In the ongoing corona pandemic, the importance of rapid diagnosis has really been emphasized. Tests have been developed at record speed to detect the presence of SARS-CoV-2 virus, so-called PCR tests and also tests that show whether antibodies have been developed, so-called serological tests.

In addition, rapid diagnosis is needed to be able to assess how seriously ill an infected patient is at risk of becoming. Especially since many patients show a rapid and acute deterioration. A large number of consistent scientific research studies have since the spring of 2020 shown that LDH (lactate dehydrogenase) is one of the most important biomarkers for disease assessment. Elevated LDH levels are associated with a 6-fold increase in the risk of serious illness and a 16-fold increase in the risk of mortality. Measurement of LDH has been included in the IFCC * guidelines for monitoring covid-19 patients since October 2020.

Being able to quickly detect elevated LDH values ​​provides the opportunity to identify patients at risk, predict the degree of severity, start treatment and thereby improve the prognosis. Measurement of LDH is today analyzed in hospital laboratories, but now Calmark has launched the world's first POC test for assessment of COVID-19, which in a few minutes, with the help of just a few drops of blood, measures LDH exactly where the patient is.

* IFCC Interim Guidelines on COVID-19 Testing in Clinical Laboratories – October 2020
(IFCC - The International Federation of Clinical Chemistry and Laboratory Medicine)

The platform Calmark POC - Covid

Calmark is already developing a point-of-care diagnostic instrument (POC) for newborns, where LDH is one of the tested biomarkers. During childbirth, newborns can suffer from lack of oxygen (asphyxia), which leads to an increase of LDH in the blood.

By adapting the measuring range to adult patients, an LDH test for assessment of severity in COVID-19 could be developed quickly. The test is based on the same test cassette and instrument as the Neo products.

The measuring instrument can be used close to the patient, for example in an emergency room. The platform consists of a portable instrument and a single-use test cassette for LDH.

POC-Analyzer Covid

Calmark POC-Analyzer is a portable, battery-powered and self-instructional instrument that will work with Calmark's POC test cassette. Each test contains the information required for automatic calibration of the results. When closing the lid of the instrument, the test is activated and a numeric value is displayed on the screen.

Blood samples may be analyzed wherever the patient is located, for example in an emergency room. The platform is adapted for hospital environment and is intended for in vitro diagnostics.

  • Safe and easy to use
  • The test results will appear on the screen within minutes
  • Battery capacity: eight working hours, charged with micro-USB connector, charger included
  • Data storage: 25 results are stored locally in the instrument
  • Calibrated during manufacturing and does not need to be further calibrated

The test COVID19-LDH

The Calmark COVID19-LDH test measures the concentration of LDH in whole blood in patients diagnosed with the SARS-CoV-2 virus. The test is used to assess the degree of disease in COVID-19.

  • Fast and quantitative assessment of severity in COVID-19 patients
  • For quantification of LDH within the relevant clinical range
  • Portable instrument
  • Results within minutes and easy to use
  • Innovative filter technology
  • Colorimetric measurement method
  • Automatic calibration
Bilirubin
-
CE marked in
April 2020
LDH
Glucose

Other tests in Development

Patents

Patent number
Country
Description
0602158-8
Sweden
Method of determining hypoxia in scalp blood during childbirth
5655307
Japan
Method of determining hypoxia in scalp blood during labor
8945824
USA
Method of determining hypoxia
0950717-9
Sweden
Test system for determining hypoxia-induced cellular damage
1050958-6
Sweden
Testing system for determining hypoxia induced cellular damage
1151115-1
Sweden
System and method for analyzing the risk or presence of organ failure
1151116-9
Sweden
In vitro method for analyzing a comparision of an indicative numberic value to a predetermined threshold so as to asses a likelihood of risk or presence of organ failure
ZL201080054087.0
China
Testing system setup and method for testing
9045792
Sweden
Testing system setup and method for testing
9228953
USA
Testing system arrangement and method for testing
1750028-1
Sweden
POC testing system for biomarkers
21005
Vietnam
Method of determining hypoxia
21008
Vietnam
Testing system setup and method for testing
540437
Sweden
Detection of a biomarker in a sample of a flowable substance
543001
Sweden
Detection of the presence of a biomarker in a sample of a flowable substance. A method of detecting the presence of a biomarker
543002
Sweden
Detection of the presence of bilirubin in a sample of a flowable substance. A method of detecting the presence of bilirubin